FirstEnergy Corp. vs Heron Therapeutics Inc — how do they compare? FirstEnergy Corp. trades at $46.86 (market cap $27.06B), while Heron Therapeutics Inc trades at $0.32 (market cap $63.41M). The key difference: FirstEnergy Corp. is far larger — about 426.7× Heron Therapeutics Inc's market cap, and FirstEnergy Corp. pays a 3.98% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| FE | HRTX | |
|---|---|---|
Market Cap | $27.06B | $63.41M |
Sector | Utilities | Health |
52-Week High | $51.91 | $1.49 |
52-Week Low | $42.83 | $0.33 |
Enterprise Value | $55.98B | $161.31M |
Dividend Yield | 3.98% | — |
Signals from Pluang's Aura AI — not financial advice
FirstEnergy (FE) trades at $47.47, up 0.2% today, with a bearish technical signal from indicators like the 6-day RSI at 11.10 and ADX signaling strong trend strength. The company reported Q2 2026 EPS of $0.50, slightly missing expectations, but revenue growth is supported by data center demand and a $36 billion grid investment plan. Analyst consensus is a Buy with a $52.67 price target, though technicals suggest near-term pressure.
The outlook is mixed: strong fundamentals with rising revenue and stable margins offer long-term value, but technical bearishness and high debt levels pose risks. Investment opportunity lies in grid expansion and data center growth, while risks include execution challenges and interest rate sensitivity. The stock presents a defensive play with growth potential amid volatility.
Heron Therapeutics (HRTX) trades at $0.49, down 1.64% today, with a bearish technical signal from moving averages. The company reported Q2 2026 revenue of $37.7M but missed earnings expectations with a $0.03 loss per share. Despite negative net income margins, HRTX maintains strong analyst support with 94.7% buy ratings. Recent news highlights patent litigation developments and quarterly earnings underperformance.
HRTX faces significant fundamental challenges with persistent losses and declining revenue projections, though analyst consensus remains overwhelmingly bullish. Investment opportunity exists if the company can achieve profitability and meet growth targets, but risks include ongoing operational losses, competitive pressures, and execution challenges in the biotechnology sector.
Trailing returns across standard periods
Latest headlines on both assets
FirstEnergy is one of the largest investor-owned utilities in the United States with 10 regulated distribution companies across six mid-Atlantic and Midwestern states. FirstEnergy also owns and operates one of the nation's largest electric transmission systems with 24,000 miles of lines.
Read more on FE →Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →